These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34764148)

  • 1. SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey.
    Barrie MB; Lakoh S; Kelly JD; Kanu JS; Squire JS; Koroma Z; Bah S; Sankoh O; Brima A; Ansumana R; Goldberg SA; Chitre S; Osuagwu C; Frankfurter R; Maeda J; Barekye B; Numbere TW; Abdulaziz M; Mounts A; Blanton C; Singh T; Samai M; Vandi M; Richardson ET
    BMJ Glob Health; 2021 Nov; 6(11):. PubMed ID: 34764148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey.
    Barrie MB; Lakoh S; Kelly JD; Kanu JS; Squire J; Koroma Z; Bah S; Sankoh O; Brima A; Ansumana R; Goldberg SA; Chitre S; Osuagwu C; Maeda J; Barekye B; Numbere TW; Abdulaziz M; Mounts A; Blanton C; Singh T; Samai M; Vandi MA; Richardson ET
    medRxiv; 2021 Jul; ():. PubMed ID: 34230939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Omicron SARS-CoV-2 serostatus in Sierra Leone: A cross-sectional study in a maternity hospital setting in Freetown, November/December 2022.
    Ruf S; Harding D; Sorie S; Janneh FM; Theuring S
    J Infect Public Health; 2024 Sep; 17(9):102518. PubMed ID: 39142080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020.
    Tadesse EB; Endris AA; Solomon H; Alayu M; Kebede A; Eshetu K; Teka G; Seid BE; Ahmed J; Abayneh SA; Moges B; Gerawork H; Sugerman D; Assefa Z; Abayneh A; Abate E; Taddese L
    Int J Infect Dis; 2021 Oct; 111():179-185. PubMed ID: 34411720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of SARS-CoV-2 in urban settings in three sub-Saharan African countries (SeroCoV): a study protocol for a household-based cross-sectional prevalence study using two-stage cluster sampling.
    Lorenz E; Souares A; Amuasi J; Loag W; Deschermeier C; Fusco D; Benke D; A Rakotoarivelo R; Rasamoelina MT; Rakotozandrindrainy R; Sie A; Afum-Adjei Awuah A; May J; Eibach D; Struck N
    BMJ Open; 2021 Dec; 11(12):e056853. PubMed ID: 34921091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey.
    Mutevedzi PC; Kawonga M; Kwatra G; Moultrie A; Baillie V; Mabena N; Mathibe MN; Rafuma MM; Maposa I; Abbott G; Hugo J; Ikalafeng B; Adelekan T; Lukhele M; Madhi SA
    Int J Epidemiol; 2022 May; 51(2):404-417. PubMed ID: 34718591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
    Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
    BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Prevalence of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (Anti-SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey.
    Nkuba AN; Makiala SM; Guichet E; Tshiminyi PM; Bazitama YM; Yambayamba MK; Kazenza BM; Kabeya TM; Matungulu EB; Baketana LK; Mitongo NM; Thaurignac G; Leendertz FH; Vanlerberghe V; Pelloquin R; Etard JF; Maman D; Mbala PK; Ayouba A; Peeters M; Muyembe JT; Delaporte E; Ahuka SM
    Clin Infect Dis; 2022 Mar; 74(5):882-890. PubMed ID: 34089598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June-October 2020.
    Coyer L; Boyd A; Schinkel J; Agyemang C; Galenkamp H; Koopman ADM; Leenstra T; Moll van Charante EP; van den Born BH; Lok A; Verhoeff A; Zwinderman AH; Jurriaans S; van Vught LA; Stronks K; Prins M
    BMJ Open; 2022 Jan; 12(1):e052752. PubMed ID: 34992110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of COVID-19 infection among vaccine naïve population after the second surge (June 2020) in a rural district of South India: A community-based cross-sectional study.
    George CE; Inbaraj LR; Rajukutty S; Joan RF; Suseeladevi AK; Muthuraj S; Chandrasingh S
    PLoS One; 2022; 17(3):e0265236. PubMed ID: 35271669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological Trends of Coronavirus Disease 2019 in Sierra Leone From March 2020 to October 2021.
    Liu Z; Gao L; Xue C; Zhao C; Liu T; Tia A; Wang L; Sun J; Li Z; Harding D
    Front Public Health; 2022; 10():949425. PubMed ID: 35844842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community health workers' job satisfaction in Ebola-stricken areas of Sierra Leone and its implication for COVID-19 containment: a cross-sectional mixed-methods study.
    Koroma O; Chen Y; Wang P; Chen G; Lin Q; Cheung MY; Zhu J
    BMJ Open; 2021 Oct; 11(10):e051645. PubMed ID: 34670763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamic change of SARS-CoV-2 variants in Sierra Leone.
    Lin L; Zhang J; Rogers J; Campbell A; Zhao J; Harding D; Sahr F; Liu Y; Wurie I
    Infect Genet Evol; 2022 Mar; 98():105208. PubMed ID: 34999288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020.
    Munywoki PK; Nasimiyu C; Alando MD; Otieno N; Ombok C; Njoroge R; Kikwai G; Odhiambo D; Osita MP; Ouma A; Odour C; Juma B; Ochieng CA; Mutisya I; Ngere I; Dawa J; Osoro E; Njenga MK; Bigogo G; Munyua P; Lo TQ; Hunsperger E; Herman-Roloff A
    F1000Res; 2021; 10():853. PubMed ID: 35528961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.